Effect of comorbidity on urinary neopterin in patients with breast carcinoma

Melicharová, Karolina; Kalábová, Hana; Krčmová, Lenka Kujovská; Urbánek, Lubor; Solichová, Dagmar; Melichar, Bohuslav

doi:10.1111/j.1365-2354.2008.01058.x

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…diabetes mellitus, atherosclerosis, hyperlipidemia, thyroid or cardiac disorders). Two or more comorbidities had a cumulative effect and were associated with higher levels of neopterin [ 62 ].…”

Section: Resultsmentioning

confidence: 99%

Prognostic factors in elderly patients with breast cancer

et al. 2013

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) remains principally a disease of old ages; with 35-50% of cases occurring in women older than 65 years. Even mortality for cancer increases with aging: 19.7% between 65 and 74 years; 22.6% between 75 and 84 years; and 15.1% in 85 years or more.The study was aimed to investigate specific predictive factors for elderly patients so to select the best way to treat and follow these patients.MethodsA search was performed on Medline, Embase, Scopus using the following Key words: Breast cancer, Breast neoplasms, Aged, Elder, Elderly, Eldest, Older, Survival analysis, Prognosis, Prognostic factors, Tumor markers, Biomarkers, Comorbidity, Geriatric assessment, Axilla, Axillary surgery. 3029 studies have been retrieved. Paper in which overall or disease free survival were not end points, or age class was not well defined, or the sample was too small, were excluded. At last 42 papers fulfilled the criteria.Results and discussionLack of screening and delay in diagnosis may be responsible for the minor improvement in survival observed in elderly respect to younger breast cancer patients. Predictive factors are the same and must be assessed with the same attention reserved to younger women.ConclusionsMost of elderly patient are fit to undergo standard treatment and can get the same benefits of younger women. Nevertheless it is possible that some older women with early breast cancer can be spared too aggressive treatments. Geriatric assessment and co-morbidities can affect the prognosis modifying surveillance, life expectancy and compliance to therapies. They can thus be useful to select the better treatment, either surgical or radio or hormone - or chemo-therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic factors in elderly patients with breast cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…It may have resulted from co-morbid diseases such as atherosclerosis, malnutrition or chronic obstructive pulmonary diseases that led to chronic immune activation [12,18]. Melicharova et al has demonstrated that presence of two or more comorbid conditions and older age than 70 years resulting in significantly increased urinary neopterin levels in breast carcinoma patients [19].…”

Section: Discussionmentioning

confidence: 99%

Serum neopterin as a prognostic indicator in patients with breast carcinoma

et al. 2010

View full text Add to dashboard Cite

AbstractNeopterin is a useful indicator of the activation state of the cellular immune system, and an elevated level predicts prognosis in different types of tumors. The aim of this study was to evaluate serum neopterin levels if it is viable predictor for prognosis in breast carcinoma patients. Serum neopterin was investigated in 56 breast carcinoma patients, 16 patients with benign breast lesions and 16 healthy women as controls. Neopterin was measured by ELISA (Enzyme-linked immunosorbent assay). The clinicopathological parameters were determined by reviewing both medical charts and pathological records. All patients had been followed-up until September 2009 or death.The mean serum neopterin concentrations were 8.5 ± 5.2 nmol/L in patients with breast carcinoma, 6.5±3.1 nmol/L in patients with benign breast lesion and 8.1 ± 1.9 nmol/L in healthy volunteers (p>0.05). Elevated neopterin levels were significantly correlated with age, elevated serum CRP level, advanced stage and presence of the distant metastases (p<0.05). Overall survival was significantly shorter in patients with a serum neopterin level >10 nmol/L than patients with neopterin <10 nmol/L level (56 months vs. 76 months, p=0.011). Increased preoperative serum neopterin concentrations are associated with a poor prognosis in patients with breast carcinoma.

show abstract

“…Neopterin is a biomarker of immune activation increased in different disorders associated with immune activation, including cancer [24]. Increased levels of neopterin in the serum and urine have been described in several malignancies such as lung [25], endometrial [26], thyroid [8] and breast cancers [27]. It was shown that neopterin levels in patients with malignant breast disease were significantly higher than in the benign group [28].…”

Section: Resultsmentioning

confidence: 99%

Neopterin: a possible biomarker in gastrointestinal cancer

BABA¹

2018

Ankara Üniversitesi Eczacılık Fakültesi Dergisi

View full text Add to dashboard Cite

Objective: Cancer, one of the major causes of death in the world, is described as a hyperproliferative disorder. Inflammation which is a primary innate immune response to perturbed tissue homeostasis, has become an important hallmark of cancer. Neopterin is produced by activated macrophages upon stimulation with proinflammatory cytokines. It is immune activation biomarker increased in different disorders associated with immune activation, including cancer. We aimed to determine the neopterin levels in gastrointestinal cancers (GIC) and to evaluate the differences among the subgroups. Material and Method:The study included 108 patients with GIC and 25 healthy controls. Patients were divided into three subgroups. The first group consisted of 40 individuals with gastric cancer, the second group consisted of 40 individuals with colorectal cancer, and the third group consisted of 28 individuals with pancreatic, liver or esophageal cancer. Serum neopterin levels were measured by ELISA.Result and Discussion: Neopterin was significantly higher in all patient groups compared to controls (p<0.05). It was found that HDL-cholesterol, albumin and total protein levels were significantly lower in all patient groups compared to controls. Our results show that neopterin levels are elevated in gastrointestinal cancers. Therefore, neopterin may be a potential predictive marker in GIC patients.

show abstract

Effect of comorbidity on urinary neopterin in patients with breast carcinoma

Cited by 4 publications

References 19 publications

Prognostic factors in elderly patients with breast cancer

Prognostic factors in elderly patients with breast cancer

Serum neopterin as a prognostic indicator in patients with breast carcinoma

Neopterin: a possible biomarker in gastrointestinal cancer

Contact Info

Product

Resources

About